
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
β-1,3-Gal-T5 CRISPR/Cas9 KO Plasmid (h) | sc-409777 | 20 µg | $397.00 | |||
β-1,3-Gal-T5 HDR Plasmid (h) | sc-409777-HDR | 20 µg | $445.00 |
B3GALT5 encodes β-1,3-Gal-T5, a Golgi-resident glycosyltransferase that catalyzes β1,3-galactosylation steps contributing to the biosynthesis of type 1 chain glycans and related lacto-/globo-series glycolipids and glycoproteins. By shaping cell-surface and secreted glycoconjugate structures, β-1,3-Gal-T5 influences glycan-dependent processes including protein trafficking, receptor organization, cell–cell adhesion, and immune recognition. Altered B3GALT5 expression or activity can remodel glycosylation patterns and has been associated with dysregulated carbohydrate antigens observed in disease-relevant contexts, including oncogenic transformation and inflammatory microenvironments. These functions position B3GALT5 as a useful target for studying glycan biosynthesis pathways and glycoproteomics-driven mechanisms of cell signaling and phenotype.
β-1,3-Gal-T5 CRISPR/Cas9 KO Plasmid (h) is a pool of plasmids designed for targeted disruption of the B3GALT5 gene in human cell lines. Each plasmid in the pool co-expresses a unique sgRNA, targeting a distinct site within the B3GALT5 locus, alongside the Streptococcus pyogenes Cas9 nuclease, and encodes GFP to enable fluorescent identification and enrichment of successfully transfected cells. This multi-guide strategy increases the likelihood of inducing frameshifts or deletions that produce a functional knockout, offering a more robust alternative to single-guide approaches. DSBs induced at multiple sites are resolved through non-homologous end joining (NHEJ) or, when used with the included HDR donor template, homology-directed repair (HDR) at a defined target site within the locus.
When used in conjunction with the RFP-expressing HDR donor, GFP and RFP fluorescence can be used together to distinguish transfected from edited cell populations, streamlining flow cytometry-based sorting and clone selection workflows.
For applications requiring confirmed, selectable knockout clones, β-1,3-Gal-T5 HDR Plasmid (h) includes an HDR donor construct containing a puromycin resistance cassette (PuroR) and a red fluorescent protein (RFP) reporter, flanked by homology arms specific to a defined B3GALT5 target site.
When co-transfected with β-1,3-Gal-T5 CRISPR/Cas9 KO Plasmid (h):
The HDR donor construct features loxP sites flanking the PuroR-RFP selection cassette to allow clean marker removal following clone confirmation. Transient expression of Cre recombinase via the included Cre Vector: sc-418923 excises the cassette, leaving a minimal residual loxP site within the B3GALT5 locus and eliminating potential confounding effects on downstream assays.
This two-step approach:
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.